共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
丙戊酸钠对氯氮平血药浓度和疗效的影响 总被引:3,自引:0,他引:3
目的:探讨合用丙戊酸钠对氯氮平治疗精神分裂症时的血药浓度和疗效的影响。方法:将80例男性精神分裂症患者随机分为两组,单用组40例患者单服氯氮平,合用组40例患者同时服用氯氮平及丙戊酸钠,分别于治疗前、治疗1周和4周末测定氯氮平的血药浓度,同时评定阳性与阴性症状量表(PANSS)、治疗中出现的症状量表(TESS)。结果:合用组治疗1周和4周末有部分患者氯氮平血药浓度升高,部分患者降低,与基线期相比,治疗4周末有显著降低。结论:合用丙戊酸钠后氯氮平血药浓度治疗4周末显著降低;丙戊酸钠可以提高氯氮平对阳性症状的疗效。 相似文献
3.
Antiepileptic effect and serum levels of clorazepate on children with refractory seizures 总被引:1,自引:0,他引:1
Clorazepate dipotassium is rapidly decarboxylated to yield desmethyl diazepam. The antiepileptic effect of clorazepate was studied in 29 epileptic children with refractory seizures. Their ages were ranged from one year 9 months to 20 years (mean 11 years 6 months). Serum clorazepate levels were also determined in 16 patients. The mean initial dose was 0.91 mg/kg/day, and the dose was increased up to 3 mg/kg/day. Within several days after initiation of clorazepate therapy, a decrease in seizure frequency was seen in patients in whom clorazepate was effective. Excellent results (decrease in seizure frequency by more than 80%) were obtained in 7 patients (24.1%), a moderate improvement with a 50 to 80% decrease was seen in 7 patients (24.1%), and a partial improvement with less than 50% decrease was seen in 7 patients (24.1%). No benefit was seen in 8 patients (27.7%). Serum clorazepate levels in patients with excellent results were 31 to 77 ng/ml (mean 55 ng/ml), those in patients with a moderate improvement were 130 to 225 ng/ml (mean 163 ng/ml), and those in patients with a partial improvement were 142 to 518 ng/ml (mean 273 ng/ml). Serum clorazepate levels in patients with no benefit were 34 to 97 ng/ml (mean 56 ng/ml). There was no direct relationship between serum clorazepate levels and clinical response. The results of this study indicate the efficacy of clorazepate for epileptic children with refractory seizures. 相似文献
4.
BACKGROUND: Scholars have investigated the differences in drug metabolism and pharmacodynamics between valproate and its sustained-release tablets only from the angle of pharmaceutical sciences or clinical practice. Whether the fact that differences in drug efficacy and time-effect of different doses of valproate and different types of sustained-release valproate tablets at the same concentration can be quantitatively reflected by determining the changes in convulsive threshold pre- and post-administration in rat models of determining the convulsive threshold developed by direct cortical electrical stimulation remains unclear.
OBJECTIVE: This study aimed to compare the drug efficacy and time-effect among magnesium valproate, sustained-release magnesium valproate tablet and depakine chrono in the treatment of epilepsy by determining the convulsive threshold of rat models created by direct cortical electrical stimulation, and human serum drug concentration before and after administration.
DESIGN: A controlled observational experiment.
SETTING: Research Institute of Epilepsy, Shanxi Medical University.
MATERIALS: Adult health male SD rats of clean grade, weighing 200–220 g, provided by the Laboratory Animal Center of Shanxi Medical University. The protocol was carried out in accordance with requests from Animal Ethics Committees for guidance. Magnesium valproate (Lot No. 041004) and sustained-release magnesium valproate tablet (Lot No. 050501) were produced in Hunan Xiangzhong Pharmaceutical Co., Ltd.
METHODS: This study was carried out in the Laboratory for Epilepsy, Shanxi Medical University between June and August 2005. ①All the SD rats were created into models for determining cortical convulsive threshold. They were randomly divided into 4 groups with 20 rats in each: magnesium valproate tablet group , sustained-release magnesium valproate tablet group, depakine chrono group and control group. After being modeled, the rats in the first 3 groups were intragastrically administrated with magnesium valproate, sustained-release magnesium valproate tablet and depakine chrono, respectively, while the control group were intragastrically administrated with the same volume of normal saline. ②Convulsive threshold of each fasting rat was determined 0.5 hour before, and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 and 24 hours after single administration, separately. ③ Convulsive threshold was determined repeatedly 2 weeks after single administration. Each rat was administrated two times daily successively. Convulsive threshold was determined 0.5 hour before, and 0.5, 2.5, 7 and 12 hours after administration, separately. ④Hepatic and renal tissues were harvested for pathological examination after 1 month of administration. ⑤Nine healthy voluntary medical stuffs were recruited in this study. Written informed consents of experiment were obtained each involved subject. The study was given an approval by the Ethics Committee of Shanxi Medical University. According to the scheme, the 9 volunteers were randomly assigned into 3 groups, in which, volunteers were asked to take magnesium valproate 500 g, sustained-release magnesium valproate tablet 500 g and depakine chrono 500 g, respectively, in the morning under the condition of fasting. Serum drug concentration of each drug was determined by fluorescence polarization immunoassay at different time points.
MAIN OUTCOME MEASURES: ① Rat convulsive threshold after single and repeated administrations. ②Hepatic and renal pathological examination results. ③ Serum drug concentration in vivo.
RESULTS:①Rat convulsive threshold after single and repeated administrations: Drug efficacy in the magnesium valproate tablet group reached to a peak level 1 to 2 hours after single administration, and was obviously higher than that in the other groups 1 hour after administration (P < 0.05). Drug efficacy in the sustained-release magnesium valproate tablet group and depakine chrono group both reached to a peak level 7 hours after administration, and was significantly higher than that in the control group (P < 0.05). After repeated administrations, the average peak valley deviation of the convulsive threshold in the magnesium valproate tablet group was 120–150 μA, which was 2 and 2.5 times as that in the sustained-release magnesium valproate tablet group and depakine chrono group, respectively. After repeated administrations for 10 times, convulsive threshold was increased by 440μA in the sustained-release magnesium valproate tablet group, and by 230 μA in the depakine chrono group in comparison with before administration. ②Hepatic and renal pathological examination results: No obvious differences in hepatic and renal impairment were found among the 4 groups after 1 month of administration successively. ③ Serum drug concentration in vivo: Serum-drug concentration of magnesium valproate was increased fast and reached to a peak level 0.5–2 hours after administration, remained at a relatively stable level 2–4 hours after administration, and then was slowly decreased. The drug efficacy of sustained-release magnesium valproate tablet and depakine chrono was slowly released 1–6 hours after administration, reached to a peak level at about 7 hours, and could last for about 16 hours.
CONCLUSION: Magnesium valproate has a rapid onset and offset of action. Sustained-release magnesium valproate tablet has a slow onset but long duration of drug efficacy. Depakine chrono can be easier to be absorbed than sustained-release magnesium valproate tablet, but its long-term effect on improving the convulsive threshold is inferior to sustained-release magnesium valproate tablet. 相似文献
5.
Plain tablets of sodium valproate (VPA), a useful antiepileptic drug, are bitter tasting and produce gastric irritation which leads to poor patient compliance. We have studied the steady state serum levels of VPA which can be produced in epileptic patients before and after a 1 week treatment with a plain tablet (Deprakine) versus an enteric coated tablet (Orfiril). The latter drug produced in most patients a higher drug fasting blood level than the uncoated preparation (22%). The enteric coated tablets appeared also better tolerated. 相似文献
6.
T Honda 《Brain & development》1984,6(1):17-21
To clarify the biochemical mechanism of convulsions from a view point of the amino acid metabolism, the free amino acid patterns in brains of El mice were investigated. The free amino acid levels in the brain excluding the cerebellum were measured by an amino acid autoanalyzer. 1) In the convulsion group, the free aspartic acid and serine levels in brains increased compared to the preconvulsion group. 2) In the postconvulsion group, an increase of glutamine and alanine levels in brains and a decrease of cystathionine level were found compared to the convulsion group. 3) It was found that in the preconvulsion group, the cystathionine and ornithine levels were high and the serine, alanine and GABA levels were low compared to the postconvulsion group. These results suggest that the free amino acid balance in the brain of this mouse should play an important role in the inducing mechanism of convulsions. 相似文献
7.
Objective: Acute encephalitis with refractory repetitive partial seizure (AERRPS) is a peculiar type of post-encephalitic/encephalopathic epilepsy. Here we report an analysis of AERRPS in a series of children and propose an effective treatment option for seizure control in these children. Methods: We retrospectively reviewed cases of AERRPS treated in a pediatric intensive care unit, between February 2002 and June 2006. Clinical characteristics were systemically assessed. Burst suppression coma was induced by high-dose suppressive therapy; 24-h electroencephalogram (EEG) monitoring was performed on each patient. The goal of treatment was to achieve complete clinical seizure control or burst-suppression pattern on EEG, aiming for an interburst interval of >5 s. Brain imaging was done for each patient. Results: There were nine patients (seven boys), aged 5–15 years. Clinical symptoms included fever (100%), upper respiratory symptoms (66.7%) and altered consciousness (66.7%). All patients received multiple high-dose suppressive drugs and were intubated with/without inotropic agents. Seizures in three patients were stopped after high-dose lidocaine infusion (6–8 mg/kg/h) in the acute stage and three patients were stopped after high dose phenobarbital (serum level 60–80 ug/mL) combined with high-dose oral topiramate (15–20 mg/kg/day). Follow-up for this study was 16–61 months. Two subjects died while seven developed epilepsy and/or neurologic deficits; none returned to baseline. All survivors were discharged and continued multiple antiepileptic medications. Conclusions: Our data indicates that children with AERRPS have high mortality and morbidity rates. High-dose topiramate combined with high-dose lidocaine infusion or high-dose phenobarbital in the acute stage might be an effective treatment option for children with AERRPS. 相似文献
8.
目的探讨丙戊酸(VPA)和托吡酯(TPM)对癫癎患儿游离肉毒碱的影响。方法35例癫癎患儿,年龄6~8岁,男20例,女15例,其中12例予VPA单药治疗,11例予TPM单药治疗,12例予VPA及TPM联合治疗6~8个月。15例健康儿童作为正常对照组。测定血浆游离肉毒碱的浓度。结果VPA组血浆游离肉毒碱的浓度明显低于对照组及TPM组,VPA-plus- TPM组与VPA组比较差异无显著性,TPM组与对照组比较差异无显著性。结论VPA可降低癫癎患儿血浆游离肉毒碱水平,而TPM对血浆游离肉毒碱无明显影响。 相似文献
9.
Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children 总被引:9,自引:0,他引:9
E.P. Calandre R. Dominguez-Granados M. Gomez-Rubio J.A. Molina-Font 《Acta neurologica Scandinavica》1990,81(6):504-506
The Wechsler Intelligence Scales for Children was applied to 64 epileptic children and 60 healthy subjects; patients followed chronic treatment with valproic acid (n = 32) or phenobarbital (n = 32). None of the children suffered mental retardation or neurological abnormalities. The test was repeated after a 9-12 month interval: 26 of the valproate treated children and 23 of the phenobarbital-treated children performed the second evaluation. At baseline, total, verbal and performance IQ scores of children receiving phenobarbital were lower than those of controls. When the results of the first and the second tests were compared, a significant increase in IQ scores was detected among controls and patients treated with valproic acid, but not among phenobarbital-treated patients. It is concluded that long-term phenobarbital therapy induces a significant impairment in learning ability whereas long-term valproate therapy does not exert a noticeable noxious effect at this respect. 相似文献
10.
目的 探讨丙戊酸钠治疗全面强直阵挛性发作相关认知功能障碍的影响因素。方法 选取2017年1月至2019年5月在我院就诊的80例小儿全面强直阵挛性发作癫痫患者作为研究对象。所有患儿均给予丙戊酸钠治疗,后依据韦氏儿童智力量表(WlSC-CR)智商得分分为认知正常组(≥ 80分)和认知障碍组(<80分)。分析丙戊酸钠治疗3个月后认知功能障碍的影响因素。结果 两组患儿的发病年龄、每月发病频率、治疗剂量及疗程比较,差异有统计学意义(P<0.05)。回归分析显示,发病年龄<5岁、每月发病频率≥ 3次、治疗剂量≥ 35 mg/(kg·d)、治疗疗程≥ 6个月是丙戊酸钠治疗小儿癫痫后认知功能障碍的危险因素(P<0.05)。认知障碍组治疗3个月后每月发病频率、治疗剂量、治疗疗程与VIQ、PIQ、FIQ呈负相关(P<0.05);发病年龄与VIQ、PIQ、FIQ呈正相关(P<0.05)。结论 发病年龄<5岁、每月发病频次≥ 3次、治疗剂量≥ 35 mg/(kg·d)、治疗疗程≥ 6个月是丙戊酸钠治疗小儿癫痫后认知功能障碍的危险因素。 相似文献
11.
12.
PURPOSE: We examined the association between seizure clustering and convulsive status epilepticus (SE) in patients with intractable complex partial seizures, to identify whether patients whose seizures typically cluster are at high risk for convulsive SE (CSE). METHODS: Seventy-six patients with intractable complex partial epilepsy who underwent presurgical evaluation in the Montefiore Epilepsy Management Unit from 1993 to 1997 were contacted and interviewed about typical seizure frequency and distribution and history of CSE. Seizure clustering was defined as three or more complex partial seizures within a 24-h period, with return to baseline between seizures. RESULTS: Of the 76 patients contacted, 21 (28%) had experienced at least one episode of CSE, and 36 (47%) typically experienced clustered seizures. SE occurred in 16 (44%) of 36 patients with clustered seizures, and in five (12.5%) of 40 patients with nonclustered seizures (p < 0.002). Of 53 patients with temporal lobe epilepsy, CSE occurred in 13 (50%) of 26 patients with clustered seizures, and four (14.8%) of 27 patients with nonclustered seizures (p < 0.006). CONCLUSIONS: Patients with intractable complex partial or localization-related epilepsy who typically experience seizure clustering are at a significantly higher risk for CSE than are patients with nonclustered seizures. 相似文献
13.
Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital 总被引:3,自引:0,他引:3
E. P. Calandre C. Rodriguez-Lopez A. Blazquez D. Cano 《Acta neurologica Scandinavica》1991,83(4):250-253
Serum lipids, lipoproteins and apolipoproteins A and B were measured in 101 epileptic patients receiving chronic treatment with valproic acid, carbamazepine or phenobarbital and in 75 age- and sex-matched control subjects. In relation to controls, subjects treated with valproic acid showed significantly lower values of total and LDL-cholesterol levels; subjects treated with carbamazepine showed significantly higher values of HDL-cholesterol and apolipoprotein A concentrations and subjects treated with phenobarbital showed significantly higher values of total cholesterol, HDL-cholesterol, apolipoprotein A and apolipoprotein B levels. The total cholesterol/HDL-cholesterol ratio was significantly lower in patients receiving valproic acid or carbamazepine but not in the phenobarbital-treated group. Changes in serum lipids profile did not correlate with drug plasma concentrations nor the duration of the treatment. 相似文献
14.
T Honda 《Brain & development》1984,6(1):22-26
To elucidate the changes of free amino acid patterns in brains of El mice induced by several anticonvulsants, the free amino acid levels in brains were measured by an amino acid autoanalyzer 24 hours after intraperitoneal injection of PB, PHT or vitamin B6 or subcutaneous injection of ACTH. Compared to the preconvulsion group, the total free amino acid level increased in the ACTH group clearly. In the PB group, the levels of threonine, glutamine, lysine, histidine and homocarnosine increased and that of ornithine decreased; in the PHT group, an increase of glutamine and histidine and a decrease of beta-alanine and ornithine were observed; in the ACTH group, an increase of aspartic acid, threonine, serine, glutamic acid, glutamine, alanine and GABA and a decrease of cystathionine and ornithine were also observed; and in the vitamin B6 group, an increase of taurine and a decrease of cystathionine were recognized. These facts suggest that the sedative activity of these drugs except ACTH might be partially explained by the increase of inhibitory amino acids in the brain, such as glutamine, homocarnosine and taurine, and that of ACTH by the dehydration of the brain, resulting in concentration of many free amino acids. 相似文献
15.
YOSHIHIKO OHBO MD HIROSHI FUKUZAKO MD KOUZOU TAKEUCHI MD MORIKUNI TAKIGAWA MD 《Psychiatry and clinical neurosciences》1996,50(2):89-90
Abstract The case study of a schizophrenic patient with argyria which resulted from the chronic and excessive ingestion of antismoking pills contain silver, is presented. Convulsive seizures developed after the patient had been addicted to the pills for 40 years. An extremely high concentration of silver was detected in serum. This case provides support for the hypothesis that silver may cause convulsive seizures as a result of systemic poisoning. 相似文献
16.
R. Kamiński B. Przywara M. Gasior Z. Kleinrok S. J. Czuczwar 《Journal of neural transmission (Vienna, Austria : 1996)》1998,105(2-3):133-146
Summary. 5-Fluoroindole-2-carboxylic acid, an antagonist of the glycine site within the NMDA receptor complex, administered intraperitoneally
in doses of 150 and 200 mg/kg, 120 min before electroconvulsions, significantly raised the convulsive threshold from 6.8 to
7.9 and 8.3 mA, respectively. At lower doses, it did not influence the threshold. However, lethality was observed 24h after
administration of the threshold-elevating doses of this glycine site antagonist.
5-Fluoroindole-2-carboxylic acid (100 mg/kg), applied together with carbamazepine, valproate or phenobarbital, significantly
reduced their ED50 values against maximal electroshock – from 13.9 to 7.5 mg/kg, from 291 to 242 mg/kg, and from 18.6 to 11.1 mg/kg, respectively.
At the dose of 50 mg/kg, it also potentiated the protective activity of carbamazepine. However, 5-fluoroindole-2-carboxylic
acid, up to 100 mg/kg, did not affect the anticonvulsive activity of diphenylhydantoin.
When applied at doses equal to their ED50 values against maximal electroshock-induced convulsions, carbamazepine (13.9 mg/kg), phenobarbital (18.6 mg/kg) and valproate
(291 mg/kg) did not affect the motor performance of mice in the chimney test. 5-Fluoroindole-2-carboxylic acid (100 mg/kg)
produced a significant motor impairment, at 50 mg/kg it did not affect the motor performance. The combined treatment of 5-fluoroindole-2-carboxylic
acid (100 mg/kg) with carbamazepine, phenobarbital or valproate, providing a 50% protection against maximal electroshock,
resulted in motor impairment. Only the combination of 5-fluoroindole-2-carboxylic acid (50 mg/kg) with carbamazepine (8.6
mg/kg) did not significantly influence this parameter.
Almost all of the antiepileptic drugs studied, when administered at doses equal to their ED50 values against maximal electroshock, did not influence retention in the passive avoidance task, which is a measure of long-term
memory. Only valproate (291 mg/kg) worsened long-term memory. The combined treatment of 5-fluoroindole-2-carboxylic acid (100
mg/kg) with carbamazepine or phenobarbital, providing a 50% protection against maximal electroshock, did not affect the retention.
The combination of 5-fluoroindole-2-carboxylic acid (100 mg/kg) with valproate (242 mg/kg) caused a significant impairment
of long-term memory and mortality of 50% of animals 24 h following the administration. The results suggest that the blockade
of the strychnine-insensitive glycine site may lead to an enhancement of the protective activity of some conventional antiepileptic
drugs, which is associated with pronounced side-effects and lethality in some cases.
Accepted January 9, 1998; received July 28, 1997 相似文献
17.
Results of clinical and pharmacokinetic observations on sodium valproate (VPA) are reported from a long-term study in 100 children with epilepsy.
VPA is the drug of choice in patients with absences. VPA may preferably be chosen as the first drug in patients with atonic seizures partly because all treatment of these seizures is uncertain, and the effect of VPA may be striking, without side effects. When starting with VPA the great problem of drug interactions is avoided. Treating patients with intractable epilepsy has shown that VPA may be effective in all seizure types regardless of the EEG-findings. However, generalized paroxysms of spike and wave complexes in the EEG are a good prognostic sign especially when fairly regular. Side effects are few when using enteric coated tablets, but toxic effects may be serious. Control schemes of blood and liver functions are necessary. Drug fasting serum level monitoring is mandatory, especially when VPA is given in combination with other anti-epileptic drugs as interactions with these are pronounced. Optimal clinical effect is usually seen on serum levels between 300 and 600 μmol/1, which may be obtained by giving 10–20 mg/kg daily assuming that the patient is receiving VPA monotherapy, which should always be aimed at. Comedication may have to be withdrawn to obtain therapeutic serum levels of VPA due to drug interactions. 相似文献
VPA is the drug of choice in patients with absences. VPA may preferably be chosen as the first drug in patients with atonic seizures partly because all treatment of these seizures is uncertain, and the effect of VPA may be striking, without side effects. When starting with VPA the great problem of drug interactions is avoided. Treating patients with intractable epilepsy has shown that VPA may be effective in all seizure types regardless of the EEG-findings. However, generalized paroxysms of spike and wave complexes in the EEG are a good prognostic sign especially when fairly regular. Side effects are few when using enteric coated tablets, but toxic effects may be serious. Control schemes of blood and liver functions are necessary. Drug fasting serum level monitoring is mandatory, especially when VPA is given in combination with other anti-epileptic drugs as interactions with these are pronounced. Optimal clinical effect is usually seen on serum levels between 300 and 600 μmol/1, which may be obtained by giving 10–20 mg/kg daily assuming that the patient is receiving VPA monotherapy, which should always be aimed at. Comedication may have to be withdrawn to obtain therapeutic serum levels of VPA due to drug interactions. 相似文献
18.
F. Peng Y. Yang J. Liu Y. Jiang C. Zhu X. Deng X. Hu X. Chen X. Zhong 《European journal of neurology》2012,19(2):277-283
Background: Oxidative stress plays a central role in neuropathology of multiple sclerosis (MS). The patients with MS have low antioxidant status. Antioxidant therapy may represent an attractive treatment of MS. However, the relationship between neuromyelitis optica (NMO), a distinct nosologic entity or a form of MS, and antioxidant status has not fully been investigated. Objectives: To investigate the correlation between NMO and serum antioxidant status of uric acid (UA), bilirubin and albumin. Methods: The serum levels of antioxidant molecules UA, bilirubin (Tbil and Ibil) and albumin were measured in 236 individuals comprising healthy subjects and patients with NMO or MS. Results: We found that serum levels of UA, Tbil, Ibil and albumin in patients with NMO were significantly lower than those in healthy control group. Moreover, these results were also observed when the male and female cohorts were investigated separately. Likewise, the serum levels of UA, Tbil, Ibil and albumin in patients with NMO were also lower than those of patients with MS. In all groups, women had lower serum UA, Tbil, Ibil and albumin levels than men. In UA groups, women had significantly lower serum UA levels than men. Conclusion: We concluded that there were reducing serum levels of UA, bilirubin and albumin in patients with NMO. The study showed patients with NMO had low antioxidant status. As a replacement therapy to patients, administration of albumin, bilirubin and UA or theirs precursors, such as inosine of UA precursor, may be beneficial to the patients with NMO. 相似文献
19.
Gul Eryilmaz Gökben Hizli Sayar Eylem Özten Işil Göğcegöz Gül Oğuz Karamustafalioğlu Özgür Yorbik 《International journal of psychiatry in clinical practice》2014,18(4):288-292
Objective. There is very limited documentation available on the effects of valproate co-medication on the pharmacokinetics of aripiprazole in a naturalistic setting. The aim of the present study was to investigate the effect of co-medication with valproate on serum concentrations of aripiprazole in bipolar disorder patients in a clinical setting. Method. Plasma samples of bipolar disorder patients (n = 69) on a stable dose of aripiprazole 20 mg/day were analyzed by a liquid chromatography-mass spectrometry method in a routine therapeutic drug monitoring setting. Therapeutic drug monitoring was done for the entire study group before and after valproate co-administration. Results. We observed a statistically significant difference between the aripiprazole monotherapy and aripiprazole-valproate combination with respect to total aripiprazole plasma levels (p < 0.01). However, no statistically significant differences were noted in aripiprazole levels between the first week and the second week of valproate co-administration. Conclusion. In conclusion, concurrent treatment with valproate resulted in changes in the total aripiprazole plasma levels by 23%. But a lower total aripiprazole concentration during co-medication with valproate, caused by protein binding displacement, is reported being clinically insignificant in previous studies. The results from these studies are important in order to clarify clinical safety and efficacy. 相似文献
20.
白蛋白降低对脑出血患者预后的影响 总被引:3,自引:1,他引:2
目的 探讨血清白蛋白降低对脑出血患者预后的影响.方法 用病例-对照研究的方法 分析比较89例血清白蛋白(serum albumin,SAL)降低(SAL<40g/L)脑出血患者及257例血清白蛋白正常(SAL≥40g/L)脑出血患者日常活动能力(Bar-thel指数)、病死率及并发症的发生率.结果 人院时2组患者Barthel指数比较差异无统计学意义(P>0.05).1个月及3个月低血清白蛋白组患者Barthd指数与正常血清白蛋白组患者比较差异有统计学意义(P<0.05).血清白蛋白降低与脑出血患者的病死率(OR=3.01,95%CI 1.69~5.26)及肺部感染率(OR=3.17).95%Cl 1.85~5.42密切相关.结论 血清白蛋白降低与脑出血患者日常活动能力障碍、病死率及肺部感染率密切相关.营养支持治疗是脑出血综合治疗的重要方法 . 相似文献